Skip to main content
Tulane Home Tulane Home


illustration of red blood cells
Sickle cell disease research has increased over the years, and this research has allowed physicians to effectively treat patients with new treatments. Research has opened the doors to many options for people with sickle cell disease to help them live healthier, happier, lives.

Some of the clinical trials that we are currently participating in are:

1. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises.

Sponsor: Selexys Pharmaceuticals Corporation
This randomized, placebo-controlled, double-blind study is being conducted to determine the efficacy and safety of SelG1 when administered once every 4 weeks for 52 weeks to patients with a diagnosis of sickle cell disease who may or may not be receiving hydroxyurea and have experienced between 2 and 10 pain crisis in the 12 months preceding enrollment in this study.

2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects with Sickle Cell Disease

Sponsor: Pfizer
Rivipansel is a glycomimetic inhibitor of E-, P-, and L-selectins in vitro. Rivipansel has been shown to inhibit inflammation in several animal models of disease, including the mouse model of vaso-occlusive crisis (VOC) of sickle cell disease (SCD). It has also been shown to consistently improve multiple clinically meaningful measures of the VOC experience, for both the pediatric and adult subjects enrolled in the Phase 2 study (GMI-1070-201). This Phase 3 study will continue to examine rivipansel for the treatment of VOC in patients with SCD.

3. Neurocognitive Deficits In Sickle Cell Patients and Sickle Cell Trait Carriers

Investigator-Initiated, under Dr. Stacy Drury
This proposal seeks to examine the neurocognitive findings in children and adults with sickle cell disease, and sickle cell trait carriers with and without evidence of changes on MRI or abnormal Doppler CNS vascular flow.

4. Transcranial Doppler Velocity in Patients with Sickle Cell Disease on Exchange and Simple Transfusions

Investigator-Initiated, under Dr. Tammuella Singleton
This study examines whether or not, exchange and simple transfusions will decrease blood velocity in patients with sickle cell disease. The hope is that this may be the basis of future studies to determine whether TCD is an acceptable tool to measure middle cerebral artery flow as a surrogate of stroke risk. This surrogate might be useful to determine the length of interval between exchange and simple transfusions in this patient population.

5. PFAST: Patent Foramen Ovale and Stroke

Sponsor: Doris Duke Charitable Foundation (DDCF)
A multicenter controlled study to compare the prevalence of patent foramen ovale (PFO) or other potential intracardiac shunts detectible by transthoracic echocardiography (TTE) by conventional 2-D, color Doppler, and agitated saline-contrast studies in children with sickle cell disease and stroke to a control group of patients without sickle cell disease or stroke.